Final_PxB_Manuscript.pdf (137.09 kB)
Download file

Polymyxin B Self-Associated With Phospholipid Nanomicelles

Download (137.09 kB)
journal contribution
posted on 15.04.2014, 00:00 by Kenneth S. Brandenburg, Israel Rubinstein, Ruxana T. Sadikot, Hayat Önyüksel
Context: Although Polymyxin B (PXB) is an effective antibiotic for Gram-negative bacterial infections, clinical use is hampered by toxicity and protein binding, which may be overcome by delivering PXB using a safe nanocarrier. Objective: To determine whether PXB self-associates with long-circulating biocompatible/biodegradable PEGylated phospholipid nanomicelles (SSM) and change in vitro bioactivity. Materials and Methods: PXB and SSM (15 nm) composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were prepared in 10 mM HEPES buffered saline. Interactions between PXB and SSM were determined by dynamic light scattering and fluorescence spectroscopy. Anti-infective effects of PXB-SSM were tested against Pseudomonas aeruginosa strain PA01 in vitro. Results: Approximately four PXB molecules self-associated with each SSM. However, significant decrease in P. aeruginosa killing was observed with PXB-SSM relative to PXB alone (p<0.05). Empty SSM had no significant effect on bacterial growth. Discussion: PXB’s self-association with SSM resulted in mitigation of the in vitro antibacterial activity. This phenomenon could be attributed, in part, to PEG2000 hindering electrostatic interactions between cationic PXB and anionic bacterial cell wall. Conclusion: PXB association with SSM formed a stable nanomedicine, resulting in decreased bioactivity of the drug in vitro. Effectiveness of this nanomedicine in vivo is yet to be studied.


Publisher Statement

© 2012 Informa Healthcare. This is a copy of an article published in the Pharmaceutical Development and Technology © 2012 Informa Healthcare. The final publication is available at doi: 10.3109/10837450.2011.572893


Informa Healthcare





Issue date


Usage metrics